T

Thermo Fisher Scientific

Makes lab instruments, reagents and supplies

Governance & Information Data Domain Partner

Full-TimePosted on 10/16/2026
No salary listed
Mid, Senior
Bachelor's
Tijuana, Baja California, Mexico
Hybrid
Business & StrategyBusiness Analysis

About the job

Requirements
  • A bachelor's degree or an equivalent combination of education and relevant professional experience is required.
  • Four to six years of relevant experience in Data Governance, information or data management, business analysis, project delivery, technology, or related disciplines is required.
  • Working knowledge of Data Governance practices, including ownership, stewardship, data quality, metadata, policies, and standards is required.
  • Understanding of how business definitions, metadata, and information context support analytics, technology delivery, and AI is required.
  • Demonstrated experience supporting complex, cross-functional projects or transformation initiatives is required.
  • Strong organizational and coordination skills are required to coordinate multiple stakeholders, activities, dependencies, and priorities.
  • Demonstrated ability to build trusted relationships and influence stakeholders without direct authority is required.
  • Strong facilitation skills are required to guide discussions toward clear requirements, ownership, decisions, and next steps.
  • Professional proficiency in English and excellent written and verbal communication skills with business and technical audiences are required.
  • Ability to translate between business requirements, data and information concepts, and technical considerations is required.
  • Sufficient technical fluency to work effectively with Product Management, Engineering, architecture, and other technology teams is required.
  • Ability to work independently within established frameworks, recognize when specialist input is needed, and escalate issues appropriately is required.
  • Sound judgment and a collaborative, practical approach to balancing governance requirements with business and delivery needs are required.
Responsibilities
  • Serve as the primary Governance and Information partner for assigned domains, providing a consistent point of contact across Data Governance, Information Management, and AI Governance.
  • Build trusted relationships with business leaders, Data Owners, Data Stewards, business process owners, AI business and technical owners, and other key stakeholders.
  • Partner with AAD Product Management and Engineering to align governance engagement with business priorities and technology delivery.
  • Develop an understanding of each assigned domain’s business processes, data, systems, information needs, AI use, priorities, and challenges.
  • Maintain awareness of current and planned initiatives to identify governance and information needs early.
  • Help stakeholders understand applicable requirements, available capabilities, and their ownership and decision-making responsibilities.
  • Promote governance and information practices as practical ways to improve business outcomes, support trusted data, and enable responsible AI adoption.
  • Work within the Governance Integration Office intake process to understand domain requests, clarify business needs, and identify the appropriate capability teams and stakeholders.
  • Provide coordinated governance representation for complex initiatives, including ERP transformations, system implementations, data migrations, analytics and AI programs, and data platform transformations.
  • Engage throughout the initiative lifecycle, from intake and planning through design, implementation, readiness, and transition to ongoing operations.
  • Work with capability specialists to identify applicable requirements, deliverables, dependencies, risks, and review needs.
  • Partner with project and program managers to incorporate agreed governance activities and milestones into broader delivery plans.
  • Coordinate cross-functional participation and maintain clear handoffs between business teams, project teams, and governance capabilities.
  • Track assigned activities, dependencies, risks, issues, and decisions, and communicate progress and unresolved needs to stakeholders.
  • Facilitate required reviews and approvals, ensuring decisions reach the appropriate owners.
  • Escalate unresolved ownership, priority, resource, or governance issues through Governance Integration Office leadership and the appropriate capability leaders.
  • Confirm that agreed activities have designated owners and timelines, monitor progress through completion, and follow up or escalate when commitments are at risk.
  • Facilitate the identification and confirmation of Data Owners and Data Stewards and help clarify their responsibilities.
  • Support business teams in identifying and documenting critical data elements and other high-value data assets.
  • Help teams identify and address applicable data ownership, quality, access, and governance requirements.
  • Coordinate with Data Quality specialists and business stakeholders to define quality expectations, document issues, and support remediation planning and follow-through.
  • Support data access requests by helping teams clarify purpose, identify the appropriate Data Owners, and navigate the established approval process.
  • Support data readiness and migration activities by ensuring governance needs and ownership decisions are addressed.
  • Support adoption of enterprise Data Governance policies, standards, workflows, and tools.
  • Partner with Information Management to help domains organize and describe their information so it can be understood and reused by people and AI.
  • Facilitate the development and maintenance of business definitions, glossary content, metadata, and relationships between business concepts and data assets.
  • Help domain stakeholders identify authoritative information sources and clarify inconsistent definitions or terminology.
  • Coordinate domain participation in data catalog, semantic data, ontology, knowledge graph, and context layer initiatives.
  • Gather business context and requirements for Information Management specialists and support validation of resulting definitions, mappings, and relationships.
  • Support domain adoption and maintenance of catalog and metadata content in accordance with enterprise standards.
  • Help business owners and stewards fulfill their responsibilities for the accuracy and currency of domain content.
  • Help domains identify AI use that requires engagement with the enterprise AI Governance process.
  • Support identification of accountable AI business owners and responsible technical owners, as applicable.
  • Help teams document intended use, business context, affected processes, data dependencies, and other information needed for intake and review.
  • Coordinate domain participation in AI intake, inventory, assessments, specialist reviews, and lifecycle activities.
  • Work with AI Governance Operations, Responsible AI and Assurance, and relevant specialist functions to clarify requirements, evidence needs, and next steps.
  • Track assigned actions, review conditions, remediation commitments, and material changes that may require further review.
  • Help stakeholders understand when AI concerns, exceptions, or unresolved risks need to be escalated.
  • Support adoption of approved AI Governance practices while preserving the decision authority of business owners and specialist functions.
  • Connect business stakeholders with Data Governance, Information Management, AI Governance, Product Management, Engineering, and other relevant partners.
  • Translate business needs into clear governance and information requirements and explain technical considerations in language stakeholders can act upon.
  • Facilitate discussions where stakeholders have differing perspectives on ownership, definitions, requirements, risks, or priorities.
  • Influence outcomes through credibility, trusted relationships, and alignment around shared business objectives.
  • Navigate competing priorities and organizational complexity while maintaining clear expectations and constructive relationships.
  • Coach owners, stewards, and other stakeholders in applying established practices and using available capabilities.
  • Share recurring domain needs, lessons learned, and improvement opportunities with Governance Integration Office and capability leaders.
  • Contribute reusable approaches that improve consistency, reduce unnecessary effort, and strengthen domain engagement.
Desired Qualifications
  • Experience working in an enterprise governance, information management, or data management program.
  • Experience supporting data migrations, analytics or AI programs, or enterprise data platform transformations.
  • Experience working with Data Owners and Data Stewards in a federated or domain-oriented governance model.
  • Experience with data catalogs, business glossaries, or metadata management.
  • Experience with technologies such as data.world, Experian Aperture Data Studio, Databricks, or similar platforms.
  • Familiarity with data models, integrations, APIs, data pipelines, or modern enterprise data platforms.
  • Experience facilitating adoption, training stakeholders, or coaching others in governance and information practices.

About the company

T

Thermo Fisher Scientific

View

Thermo Fisher Scientific makes and sells the instruments, chemicals, consumables and lab services that drug companies, hospitals, universities and industrial labs use for research, testing and production. Its products cover work from gene sequencing and protein analysis to diagnostic tests and lab freezers, and its distribution arm ships supplies to labs worldwide. Drug developers also hire it to run clinical trials and to manufacture medicines under contract. It earns money from consumables that labs buy again and again, along with instrument sales, service contracts and outsourcing fees. The company traces its roots to Thermo Electron, founded in 1956, which merged with Fisher Scientific in 2006, and it is based in Waltham, Massachusetts.

Company Size

10,001+

Company Stage

IPO

Headquarters

Waltham, Massachusetts

Founded

1956

Get referred to Thermo Fisher Scientific

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Drugmaker demand is firming: revenue rose 10% to $11.99 billion in the June 2026 quarter, 5% excluding deals and currency.
  • Profits are outpacing sales, which supports stock grants: adjusted earnings per share rose 13% in the June 2026 quarter.
  • Career paths span many businesses: Thermo Fisher runs four segments, from diagnostics to contract drug development.

What critics are saying

  • Factory jobs are shrinking: Thermo Fisher announced in January 2026 it will close its Asheville plant, cutting 421 jobs.
  • Whole units get sold: microbiology, with $645 million in 2025 sales, went to buyout firm Astorg in August 2026.
  • Cuts reach California too: Thermo Fisher filed in January 2026 to lay off 173 Carlsbad workers by March.

What makes Thermo Fisher Scientific unique

  • Many familiar lab brands sit under one roof: Thermo Fisher owns Thermo Scientific, Applied Biosystems, Invitrogen and Fisher Scientific.
  • Thermo Fisher reaches labs through its own sales force of about 14,000 people, per its 2025 annual filing.
  • Its trial-data unit Clario has supported about 70% of FDA and EMA novel drug approvals over the past decade.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • Unlimited Paid Time Off
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Hybrid Work Options
  • 401(k) Retirement Plan
  • 401(k) Company Match

Company News

Yahoo Finance
Oct 21st, 2026
Thermo Fisher raises 2026 organic growth outlook to 4% on strong biopharma demand

Thermo Fisher Scientific raised its full-year organic revenue growth outlook to 4% on its third-quarter earnings call on October 21, 2026. The company said it beat its third-quarter revenue expectations and kept its fourth-quarter guidance at 4%. Chief executive officer Marc Casper said demand in pharma and biotech markets stayed strong, building on the improvement seen in the second quarter. Artificial intelligence built into its lab hardware cuts manual setup time by about 90%, Casper said. He added that the integration of Clario, a recent acquisition, is going smoothly, with revenue synergies expected as its clinical development tools join Thermo Fisher's wider offering.

CemNet
Oct 15th, 2026
Thermo Fisher launches automated XRD system.

Thermo Fisher launches automated XRD system. Published 15 October 2026, 08:33 Get daily news, weekly insights and market analysis in your inbox. Thermo Fisher Scientific has introduced the ARL X'TRA Pro X-ray diffractometer for automated mineralogical analysis in cement and mining laboratories. The system is designed for unattended operation, with capacity for up to 98 samples. According to the company, throughput ranges from 50 to more than 100 samples per day, depending on analytical requirements. Its X-ray source is rated at up to 3kW. For cement producers, X-ray diffraction supports the identification and quantification of mineral phases in raw materials, clinker and finished cement. Automated sample handling can help laboratories maintain routine analysis while reducing manual intervention. TOPICS IN THIS ARTICLE

Business Wire
Oct 6th, 2026
Thermo Fisher unveils OSD Express and expands drug development capabilities at CPHI Milan 2026

Thermo Fisher Scientific is showcasing expanded drug development and manufacturing capabilities at CPHI Milan 2026, running 6-8 October. The company is introducing OSD Express for oral solid dose development and expanding small molecule capabilities through collaboration with AustinPx, which provides access to KinetiSol Technology for improving drug bioavailability. The firm is investing in tableting, laboratory and packaging facilities across France, Canada and North America. For sterile products, new Steriles Express Solutions aim to deliver Phase I or II clinical trial material in 20 weeks. Thermo Fisher is also expanding bioprocessing capacity and clinical trial supply infrastructure, including a 52,000-square-foot facility in New York. The company is deploying generative AI to reduce master informed consent form drafting time by 50%. Thermo Fisher generates over $45 billion in annual revenue.

BioPharma Watch
Oct 6th, 2026
Thermo Fisher Scientific showcases new solutions and expanded capabilities to accelerate Drug Development at CPHI Milan 2026.

Thermo Fisher Scientific showcases new solutions and expanded capabilities to accelerate Drug Development at CPHI Milan 2026. Key Takeaway: Thermo Fisher Scientific is set to showcase its expanded drug development and manufacturing capabilities at CPHI Milan 2026. The company aims to assist pharmaceutical and biotechnology firms in navigating complex commercialization processes. Among its new offerings is OSD Express, designed to enhance predictability in drug development. Market sentiment analysis. Positive factors. * Thermo Fisher Scientific is expanding its drug development capabilities. * New solutions aim to help companies navigate commercialization paths. * Showcasing innovations at a major industry event enhances visibility. New development solutions, expanded global capacity, and advanced digital technologies help pharma and biotech companies reduce complexity and scale toward commercialization Key facts. - New solutions for drug product development:New OSD Express and Steriles Express Solutions provide defined development approaches designed to increase predictability and help programs advance more efficiently, while Accelerator(TM) Drug Development connects capabilities across development to reduce handoffs and maintain continuity. - Expanded capabilities and capacity:Investments across oral solid dose, sterile drug product, biologics, and clinical supply are expanding development and manufacturing capabilities globally, including new small molecule technologies through Thermo Fisher's collaboration with AustinPx. - Technology delivering measurable impact:AI, data, and digital technologies are being applied across clinical development, including generative AI applications that reduced master informed consent form draft time by 50% and, in some studies, reduced CRA site enrollment and activation activities by 15-30%. MILAN-(BUSINESS WIRE)-Thermo Fisher Scientific, the world leader in serving science, is expanding its drug development, manufacturing, and clinical capabilities to help pharmaceutical and biotechnology companies navigate increasingly complex paths to commercialization, reduce friction, and maintain momentum. The company will showcase these new and expanded capabilities at CPHI Milan 2026, Oct. 6-8. Among the new offerings isOSD Express, a defined solution designed to increase predictability and advance oral solid dose development more efficiently. The offering reflects the broader approach ofAccelerator(TM) Drug Development, which connects scientific expertise and capabilities across drug development, clinical trials, endpoint solutions, clinical supply, and laboratory services to reduce handoffs and help customers maintain continuity as programs advance. Additionally, Thermo Fisher is expanding small molecule capabilities through its collaboration withAustinPx, giving customers access to KinetiSol(TM) Technology, a solvent-free technology designed to improve the bioavailability of poorly soluble drugs and support development and scale-up through commercial manufacturing. Targeted investments in tableting, laboratory, and packaging capabilities are also expanding oral solid dose development and commercial manufacturing, including new Gerteis technology for advanced dry granulation and improved tablet manufacturing efficiency in Bourgoin, France, and Whitby, Canada, and serialized packaging capabilities in Cincinnati and Toronto. For sterile drug product programs,Steriles Express Solutionsprovide a defined approach for early development and late-stage technology transfer. Steriles Express Early Development is designed to provide Phase I or II clinical trial material in as little as 20 weeks, while Steriles Express Tech Transfer can provide a Phase III GMP batch in as little as 26 weeks.* Supporting these pathways are continued investments in sterile drug product capacity, including new and expanded lines in Plainville, Massachusetts; Monza, Italy; and Ferentino, Italy, for development and commercial manufacturing of vials and prefilled syringes. Thermo Fisher is also expanding fill-finish and drug-device capabilities in Ridgefield, New Jersey, including through its previously announcedcollaboration with SHL Medical. "Drug development increasingly depends on decisions and capabilities that span traditional boundaries, from development and manufacturing to clinical supply and clinical execution," said Mike Shafer, Executive Vice President and President, Biopharma Services, Thermo Fisher Scientific. "We're investing not only in capacity, but in how those capabilities connect. That gives our customers greater continuity as they navigate critical transitions, scale their programs, and prepare for commercialization." Strengthening capabilities across the development pathway. Beyond drug product, Thermo Fisher continues to invest in capabilities across biologics development, manufacturing, and clinical supply. New bioprocessing equipment in Plainville will expand U.S.-based cGMP monoclonal antibody manufacturing capacity, while the recently openedU.S. Bioprocess Design Centerhelps customers translate process innovations into scalable solutions for biologics development and manufacturing. Thermo Fisher has also expanded its Gibco(TM) cell culture media portfolio withCHO-K1 Catalog Panel Media and Feed, a cGMP-ready portfolio designed to support cell growth and protein production. In clinical trial supply, a 52,000-square-foot expansion in Bohemia, New York, will increase clinical label manufacturing capacity, while a new facility in Heiwajima, Tokyo, is expected to approximately double Japan's storage, distribution and secondary packaging capacity, ranging from controlled ambient to ultra-low temperature. Across the global clinical supply network, Thermo Fisher is also making significant investments in technologies supporting drug-device combination product assembly, labeling and packaging. These scalable technologies enable fit-for-phase automation, supporting programs from early clinical development through commercialization as volume and complexity increase. Applying digital technologies and data to improve development execution. Thermo Fisher is applying AI, data, and digital technologies to improve execution and support more informed decisions across clinical development. Within the PPD(TM) clinical research business, generative AI is being used to accelerate clinical development activities, including a50% aggregate reductionin master informed consent form draft time. Thermo Fisher is also expanding evidence-generation capabilities through thePPD(TM) CorEvitas(TM) Vitiligo Registry, designed to generate longitudinal real-world evidence on treatment effectiveness, disease burden, and patient outcomes. In digital clinical solutions,Clario's eCOA Swiftcaptures patient-reported data in early-stage oncology trials to help sponsors better understand tolerability and patient impact as programs advance. Thermo Fisher experts share insights at CPHI Milan. These shifts in how drug development is executed, from the role of strategic partnerships to the practical application of AI, will also be explored by Thermo Fisher experts at CPHI Milan: CDMO Consolidation: Strategic Partnerships or Dangerous Dependencies?- Hannah Spaepen, Senior Director, CMC Portfolio Management, Pharma Services, will participate as a panelist Tuesday, Oct. 6, from 11:35 a.m. - 12:20 p.m. CET. Putting AI to work in drug development: Practical applications that deliver measurable value- Anil Kane, Global Head of Technical and Scientific Affairs, Pharma Services, will present Wednesday, Oct. 7, from 1:45 - 2:10 p.m. CET. To learn more about these and other developments, visit Thermo Fisher Scientific atbooth 6A2, where specialists in drug development, manufacturing, and clinical services will be available throughout the conference to discuss customer needs and challenges. * Actual Steriles Express timelines may vary based on defined program parameters and scope. About Thermo Fisher Scientific. Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $45 billion. Its Mission is to enable its customers to make the world healthier, cleaner and safer. Whether its customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics, or the development and manufacture of life-changing therapies, BiopharmaWatch is here to support them. Its global team delivers an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through its industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD. For more information, please visit www.thermofisher.com. Frequently asked questions. What is Thermo Fisher showcasing at CPHI Milan 2026? Thermo Fisher is showcasing its expanded drug development and manufacturing capabilities. What is OSD Express? OSD Express is a new solution designed to increase predictability in drug development. When is CPHI Milan 2026 taking place? CPHI Milan 2026 will be held from October 6 to 8. Who does Thermo Fisher aim to assist? Thermo Fisher aims to assist pharmaceutical and biotechnology companies.

Yahoo Finance
Sep 28th, 2026
Thermo Fisher Scientific to resell Evosep Eno separation platform for proteomics workflows

Evosep has entered a reseller agreement with Thermo Fisher Scientific for its Evosep Eno separation platform. Through the partnership, Thermo Fisher Scientific will offer the platform as part of its mass spectrometry solutions portfolio, combining its global reach with Evosep's separation technology. The Evosep Eno platform addresses the need for standardised proteomics in research, drug discovery, and clinical applications. It delivers robustness, ease of use, and throughput whilst minimising operational complexity. Customers will be able to purchase Evosep Eno directly through Thermo Fisher Scientific. The platform enables standardised separations across laboratories, instruments, and operators, supporting reproducible results for large-scale studies. The agreement supports applications including population studies, biomarker discovery, drug development, and clinical proteomics initiatives.